Disease duration, years, median | 8.2 | 9.4 | ns | Biologics now, % (excl rituximab) | 22.5% | 13.5% | <0.001 |
CCP or RF positive, % | 73% | 76% | ns | Rituximab now, % | 10.3% | 6.1% | <0.001 |
ESR, median | 14 | 9 | <0.001 | MTX now, % | 49.6% | 67.4% | <0.001 |
CRP, median | 3 | 2 | 0.021 | Prednisolone now, % | 54.8% | 48.9% | 0.003 |
MDglobal (0–100), mean | 9.6 | 10 | ns | HCQ now, % | 2.0% | 43.1% | <0.001 |
DAS28 (0–9.4), mean | 2.7 | 2.3 | <0.001 | SSZ now, % | 3.3% | 24.0% | <0.001 |
DAS28-remission, % | 51% | 64% | <0.001 | Leflunomide now, % | 5.7% | 7.7% | 0.04 |
MHAQ (0–3), mean | 0.49 | 0.41 | <0.001 | Combin: MTX+other DMARD,% | 0.8% | 41.0% | <0.001 |
Pain (0–100), mean | 34 | 29 | <0.001 | Biologics ever, % | 42.0% | 25.0% | <0.001 |
PatGlobal (0–100), mean | 35 | 31 | <0.001 | Costs per 100 patients per year/€ | 501.497 | 269.860 | <0.001 |